• Kayak for prescription drugs
• Zillow for prescription drug prices
• Honey for prescription drugs

GoodRx's major products and services include:

• Prescription Savings Platform: A digital platform that enables consumers to compare prescription drug prices and access negotiated discounts using GoodRx codes.
• Subscription Services: Offers premium subscription plans that may provide additional savings or benefits to users.
• Pharma Manufacturer Solutions: Provides services to pharmaceutical manufacturers, likely related to patient access, adherence, or marketing.
• Telehealth Services: Offers virtual healthcare consultations and services to consumers.

GoodRx (GDRX) primarily sells its services to other companies. Its major customers fall into the following categories:

• Pharmacy Benefit Managers (PBMs): GoodRx partners with Pharmacy Benefit Managers, who pay GoodRx transaction fees when consumers utilize GoodRx codes to save money on prescription drug purchases. These PBMs manage formularies and prescription transactions between consumers and pharmacies.
• Pharmaceutical Manufacturers: GoodRx offers solutions to pharmaceutical manufacturers, which include programs designed to help patients access and afford their medications.

• CVS Health (CVS)
• Cigna (CI)
• UnitedHealth Group (UNH)
• Prime Therapeutics

Wendy Barnes, Chief Executive Officer

Wendy Barnes was appointed Chief Executive Officer and President of GoodRx, effective January 1, 2025. Prior to joining GoodRx, she served as the Chief Executive Officer of RxBenefits, Inc., a pharmacy benefits optimizer. She also held various roles at Express Scripts Holding Company, including President of Express Scripts Pharmacy, overseeing service, operations, and financial success for millions of members. Additionally, Ms. Barnes served as Group Vice President at Rite Aid and held executive positions at Pfizer. She also dedicated 10 years as a Medical Service Corps Officer in the United States Air Force.

Christopher McGinnis, Chief Financial Officer & Treasurer

Christopher McGinnis was appointed Chief Financial Officer of GoodRx in February 2025. He brings over 30 years of extensive financial leadership across the healthcare industry. Before joining GoodRx, Mr. McGinnis served as CEO of CitizensRx, a pharmacy benefits management provider, from 2021 to 2024. He previously held various executive roles at Lumeris/Essence Healthcare, a Medicare Advantage plan and value-based healthcare operator, including Chief Financial Officer and Executive Vice President of Operations. Earlier in his career, he was Chief Accounting Officer at Express Scripts Holding Company.

Trevor Bezdek, Co-founder and Co-Chair of the Board

Trevor Bezdek co-founded GoodRx in 2011. He served as Co-Chief Executive Officer and Secretary of the company from January 2015 to April 2023, transitioning to Chairman of the Board in April 2023, and later to Co-Chair. Prior to co-founding GoodRx, Mr. Bezdek was a Managing Partner at Tryarc, LLC, an information technology consulting firm, from 2001 to 2007. He also co-founded Biowire, a bioinformatics software provider.

Doug Hirsch, Co-founder and Director

Doug Hirsch co-founded GoodRx in 2011. He served as Co-Chief Executive Officer until April 2023, and is currently the Chief Mission Officer and a Director on the Board. Mr. Hirsch has a long history of building technology for consumers, having been among the first 30 employees at Yahoo!, where he created and managed early online communities such as GeoCities and Yahoo! Groups. He also served as Vice President of Product at Facebook in 2005. He founded DailyStrength, an online community for health challenges, which was acquired by HSW International in 2008. His personal experience with inconsistent prescription drug pricing was a key motivation for starting GoodRx.

Scott Wagner, Co-Chairman & Director

Scott Wagner has served as a member of GoodRx's board of directors since January 2025 and is a Co-Chairman. He previously held the role of Interim Chief Executive Officer from April 2023 to January 2025. Before joining GoodRx, Mr. Wagner held various executive roles at GoDaddy from 2012 to 2019, including Chief Executive Officer and President/Chief Financial Officer/Chief Operating Officer, where he helped triple the company's revenue to approximately $3 billion. From 2000 to 2012, he was a Partner at Kohlberg Kravis Roberts (KKR), a global private equity firm, indicating a pattern of managing companies backed by private equity firms.

Here are the key risks to GoodRx's business:

1. Reliance on Pharmacy Benefit Managers (PBMs) and Pharmacy Relationships: GoodRx's business model is heavily dependent on its relationships with a limited number of Pharmacy Benefit Managers (PBMs) and large pharmacy chains. The high concentration within the PBM market, with a few major players processing a significant majority of prescription claims, gives these entities substantial market influence and negotiation power. This concentration can impact GoodRx's ability to negotiate drug prices and maintain its extensive network of pharmacies. Shifts in these relationships, renegotiations, or the introduction of new pricing frameworks by PBMs could directly undercut GoodRx's role and value proposition. GoodRx has also faced class-action lawsuits from independent pharmacies alleging conspiracy with PBMs to fix reimbursement rates.
2. Regulatory and Policy Shifts, including Government-Sponsored Platforms: The highly regulated healthcare industry exposes GoodRx to significant risks from changes in laws and policies. New federal initiatives and policy shifts, such as government-sponsored platforms like "TrumpRx.gov," could directly compete with or significantly impact GoodRx's market position. The specific impact of such initiatives is often unclear but could be substantial. Additionally, evolving regulations concerning data privacy, telehealth services, and healthcare fraud and abuse require continuous adaptation and compliance, with any failure to comply potentially leading to significant repercussions. GoodRx previously faced an FTC enforcement action and a $1.5 million fine for improperly sharing health data, highlighting the ongoing regulatory scrutiny in this area.
3. Intense Competition and Declining User Engagement: GoodRx operates in a highly competitive digital healthcare market, facing challenges from both established players and new entrants, including other prescription discount services and large pharmacy chains like Amazon Pharmacy. The company has experienced a decline in Monthly Active Consumers (MACs) and subscription revenue, partly due to the dynamic nature of the retail pharmacy sector, such as store closures (e.g., Rite Aid bankruptcy) and the discontinuation of partnerships (e.g., Kroger Savings Club). This decline in user engagement and strong competitive pressures pose ongoing challenges to GoodRx's market share and revenue growth.

The expansion of large technology companies (e.g., Amazon) into direct-to-consumer pharmacy services, offering simplified pricing structures or subscription models (such as Amazon RxPass), which could diminish the need for third-party prescription price comparison tools and discount codes for a significant portion of the market.

• Prescription Price Comparison Platform: The estimated total addressable market for the prescription opportunity, including prescriptions that are written but not filled, ranges from $515 billion to $588 billion in the U.S. This reflects the market for prescription drugs where consumers can find savings.
• Pharma Manufacturer Solutions: GoodRx estimates the addressable market for its pharma manufacturer solutions to be $19 billion in the U.S. Another estimate from the company states this market is over $7 billion. These solutions involve partnerships with pharmaceutical manufacturers to offer discounts and foster patient relationships.
• Telehealth Services: The company's IPO prospectus from 2020 estimated a telehealth opportunity of approximately $250 billion in the U.S. More broadly, the U.S. telehealth market was valued at approximately $42.54 billion in 2024 and is projected to reach $150.13 billion by 2030.
• Subscriptions: While GoodRx offers subscription services, such as GoodRx Gold, a specific addressable market size for these standalone subscription offerings is not separately quantified in the available information.

GoodRx (GDRX) is expected to drive future revenue growth over the next two to three years through several key initiatives:

1. Growth in Pharma Manufacturer Solutions (Pharma Direct): GoodRx is strategically shifting its focus towards and expanding its Pharma Manufacturer Solutions, now branded as "Pharma Direct." This segment is consistently highlighted as a significant growth engine, with a reported 41% year-over-year growth in 2025 and an anticipated growth of at least 30% in 2026. This involves expanding direct-to-consumer affordability programs with pharmaceutical manufacturers.
2. Expansion of Integrated Savings Program (ISP) and Organic Growth in Prescription Transactions: The company is experiencing organic growth in its prescription transactions revenue, partly due to the expansion of its Integrated Savings Program. This reflects GoodRx's continued ability to leverage its core price comparison platform and strengthen relationships with retail pharmacy partners.
3. Differentiated Subscription Offerings: GoodRx is scaling its differentiated subscription offerings, particularly new condition-specific subscriptions, with weight loss subscriptions expected to contribute more significantly to revenue in 2026. Although subscription revenue experienced a temporary decline due to the sunset of the Kroger Savings Club, GoodRx Gold subscription plans have shown growth.
4. GoodRx Employer Direct Offerings: GoodRx is entering the employer market by launching "GoodRx Employer Direct." This initiative aims to broaden access to prescription savings by integrating GoodRx's solutions into employer-sponsored benefit programs.